Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;70(5):1008-1015.
doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27.

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Cihan Yurdaydin  1 , Zaigham Abbas  2 , Maria Buti  3 , Markus Cornberg  4 , Rafael Esteban  3 , Ohad Etzion  5 , Edward J Gane  6 , Robert G Gish  7 , Jeffrey S Glenn  7 , Saeed Hamid  8 , Theo Heller  9 , Christopher Koh  9 , Pietro Lampertico  10 , Yoav Lurie  11 , Michael Manns  4 , Raymundo Parana  12 , Mario Rizzetto  13 , Stephan Urban  14 , Heiner Wedemeyer  15 ; Hepatitis Delta International Network (HDIN)
Collaborators, Affiliations
Review

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Cihan Yurdaydin et al. J Hepatol. 2019 May.

Abstract

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials.

Keywords: Hepatitis D; New treatment approaches; Surrogate marker; Treatment endpoints.

PubMed Disclaimer